St. Jude Medical, Inc. (NYSE:STJ) announced it has been awarded a patent from the U.S. Patent and Trademark Office for treating depression using neurostimulation therapy in an area of the brain known as Brodmann Area 25. Brodmann Area 25 is a structure within the subcollosal gyrus region of the brain. It is the focus of the St.
Popularity: unranked [?]
Related posts:
- St. Jude Medical Announces First Patient Implants In Clinical Study Evaluating Deep Brain Stimulation For Depression
- St. Jude Medical Announces First Patient Implants In Clinical Study Evaluating Deep Brain Stimulation For Depression
- Patients In St. Jude Medical Deep Brain Stimulation For Depression Pilot Study Demonstrate Sustained Improvement In Depression Symptoms
- St. Jude Medical Announces Clinical Study Of Deep Brain Stimulation For Depression
- Brain Pathway May Underlie Depression
Comments
No Responses to “St. Jude Medical Awarded U.S. Patent For Neurostimulation Therapy For Depression”